Zobacide contains a black-box warning because the drug causes cancer in laboratory animals.
Discuss this risk with your doctor before taking this medication.
Before using Zobacide, tell your physician if you have or have ever had:
- Liver disease
- Kidney disease
- Crohn's disease
- A blood disorder (such as anemia or leukopenia)
- Epilepsy or other seizure disorders
- Nerve disorders
- Allergies to medications
This medicine only treats bacterial infections. It won't work for the common cold, the flu, or any other viral infections.
Antibiotics such as Zobacide can cause diarrhea, which could be a sign of a new infection. Call your healthcare provider right away if you have diarrhea that's severe, watery, or bloody.
Be sure to take Zobacide for the full length of time that your doctor prescribes.
Continue to take the drug even if your symptoms improve. Don't stop using Zobacide without first talking to your doctor.
Tell all of your healthcare providers that you're taking this medicine. Zobacide may cause unusual results on certain medical tests.
Your physician will probably want to test your blood often to determine your response to Zobacide.
Keep all appointments with your doctor and laboratory while taking this drug.
The Zobacide immediate-release tablet and extended-release tablet are prescription drugs. They’re both taken by mouth. These tablets are available as the brand-name drugs Flagyl (immediate-release) and Flagyl ER (extended-release).
Immediate-release drugs are released into the body right away. Extended-release drugs are released into the body slowly over time.
Both the immediate-release and extended-release tablets are available as generic drugs. Generic drugs usually cost less than the brand-name version. In some cases, they may not be available in all strengths or forms as the brand-name drug.
In patients stabilized on relatively high doses of lithium, short-term Zobacide therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning Zobacide to detect any increase that may precede clinical symptoms of lithium intoxication.
Zobacide has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity. Zobacide should not be administered concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to Zobacide are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly.